Familial hypercholesterolemia

About 1 in 250 Canadians is thought to have the familial hypercholesterolemia (FH). FH is both under diagnosed and under treated despite the knowledge that early diagnosis and treatment can normalize life expectancy. The following point of care tool contains the Canadian criteria for the clinical diagnosis of FH as well as FH clinical features.

GECKO point of care june 26th

Familial hypercholesterolemia point of care tool (More information on FH can be found in the GEC-KO on the run and the more comprehensive GEC-KO Messenger)

Additional tools and resources from FH Canada

An app for the clinical diagnosis of FH, assessing the degree of severity of FH for new patients and helps facilitate FH diagnosis, in addition to a validated algorithm to impute a baseline value from LDL-C levels while on lipid lowering medications.

The details of the developed algorithm have been published in Clinical Chemistry.

GEC-KO aims to aid the practicing non-genetics health professional by providing informed opinions regarding genetic/genomic conditions, services and technologies that have been developed in a rigorous and evidence-based manner with periodic updating.  The content on the GEC-KO site is for educational purposes only.  No resource should be used as a substitute for clinical judgement.  GEC-KO assumes no responsibility or liability resulting from the use of information contained herein.

External links are selected and reviewed at the time a page is published. However, GEC-KO is not responsible for the content of external websites. The inclusion of a link to an external website from GEC-KO should not be understood to be an endorsement of that website or the site’s owners (or their products/services).